Variant position: 273 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 393 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human TIITLEDSSGNLLGRNSFEV RVCACPGRDRRTEEENLRKKG
Rhesus macaque TIITLEDSSGNLLGRNSFEV RVCACPGRDRRTEEENFRKKG
Mouse TIITLEDSSGNLLGRDSFEV RVCACPGRDRRTEEENFRKKE
Rat TIITLEDSSGNLLGRDSFEV RVCACPGRDRRTEEENFRKKE
Pig TIITLEDASGNLLGRNSFEV RVCACPGRDRRTEEENFLKKG
Bovine TIITLEDSCGNLLGRNSFEV RVCACPGRDRRTEEENLRKKG
Rabbit TIITLEDSSGNLLGRNSFEV RVCACPGRDRRTEEENFRKKG
Sheep TIITLEDSRGNLLGRSSFEV RVCACPGRDRRTEEENFRKKG
Cat TIITLEDSNGKLLGRNSFEV RVCACPGRDRRTEEENFRKKG
Chicken TILTLEGPGGQLLGRRCFEV RVCACPGRDRKIEEENFRKRG
Xenopus laevis TIITLETPQGLLLGRRCFEV RVCACPGRDRRTEEDNYTKKR
Zebrafish TIITLETQEGQLLGRRSFEV RVCACPGRDRKTEESNFKKDQ
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 393 Cellular tumor antigen p53
102 – 292
1 – 320 Interaction with CCAR2
100 – 370 Interaction with HIPK1
100 – 300 Required for interaction with ZNF385A
116 – 292 Interaction with AXIN1
256 – 294 Interaction with E4F1
273 – 280 Interaction with DNA
269 – 269 Phosphoserine; by AURKB
284 – 284 Phosphothreonine; by AURKB
291 – 291 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
292 – 292 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
269 – 269 S -> A. Abolishes phosphorylation.
269 – 269 S -> E. Inhibits strongly its transcriptional activity.
284 – 284 T -> E. Inhibits strongly its transcriptional activity.
264 – 274
The consensus coding sequences of human breast and colorectal cancers.
Sjoeblom T.; Jones S.; Wood L.D.; Parsons D.W.; Lin J.; Barber T.D.; Mandelker D.; Leary R.J.; Ptak J.; Silliman N.; Szabo S.; Buckhaults P.; Farrell C.; Meeh P.; Markowitz S.D.; Willis J.; Dawson D.; Willson J.K.V.; Gazdar A.F.; Hartigan J.; Wu L.; Liu C.; Parmigiani G.; Park B.H.; Bachman K.E.; Papadopoulos N.; Vogelstein B.; Kinzler K.W.; Velculescu V.E.;
Cited for: VARIANTS [LARGE SCALE ANALYSIS] LEU-134; PHE-157; CYS-163; HIS-175; ARG-177; ARG-193; PRO-213; PHE-241; PHE-242; GLN-248; TRP-248; SER-249; TRP-267; LYS-271; CYS-273; HIS-273; LEU-273; SER-278; ILE-280 AND HIS-281;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.